SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

A report alleging that delays at IRENs Texas data-center site contributed to Microsofts lower AI spending has intensified selling ahead of earnings, alongside concerns that new political and permitting risks could slow future data-center expansion. Traders debate whether those risks outweigh IRENs existing power assets and international projects.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention amid a sharp semiconductor selloff, with traders linking weakness to fears that Democratic control of Congress could bring tighter AI and data-center regulation and slow infrastructure spending. The community is split between calls that the AI trade is broken and further losses lie ahead, and bullish views that the reaction is overdone and chip demand remains strong.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Democratic midterm gains have sparked concern that tighter AI and data-center rules could delay infrastructure buildouts, weighing on Nvidia and other semiconductor stocks. Traders are divided between viewing the selloff as an overreaction because AI demand remains strong and fearing slower capex, regulatory risk, and broader weakness in the AI trade.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is the focus, with a letter from 28 trial investigators backing approval and challenging the FDAs interpretation of the trial data. Many traders are bullish and anticipate a short squeeze, while others emphasize that approval is uncertain and debate the strength of the evidence and the review process.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Democratic election gains have fueled concern that tougher scrutiny or delays for data-center construction could slow AI infrastructure spending and weaken future memory demand, contributing to a sharp selloff in Micron and other chip stocks. Traders are divided between those who see the drop as an overreaction and expect AI demand to persist, and those who see a broader repricing of AI-related stocks and memory-cycle risks.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

A semiconductor and AI-stock selloff, alongside traders concerns that Democratic gains could bring tougher AI or data-center regulation, is driving interest in SOXS. Bears see room for further weakness in chips, while others expect a relief rally and caution that the leveraged inverse ETF can lose value quickly in choppy markets.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Fears that Democratic election gains could bring tighter rules or permitting hurdles for AI data-center construction have weighed on Nebius alongside other neocloud and infrastructure stocks. Traders debate whether the selloff overstates the risk given Nebiuss international footprint and limited exposure to Texas, while bears warn that slower buildouts could delay growth.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCIs sharp selloff despite a strong earnings report and raised outlook has traders debating whether margin pressure and reliance on one large customer outweigh its AI-server demand. Some also speculate that election-related uncertainty could slow data-center expansion, while bullish traders argue the AI buildout will continue and the results support the companys growth outlook.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros Q3 results and outlook are driving attention: many traders point to a weaker-than-expected full-year outlook and sluggish same-store sales and visits behind the sharp selloff, despite reported earnings and revenue beats. Bears cite slowing growth, costs, competition and valuation; bulls view the drop as overdone and see the expansion story intact, while the chairmans share sale adds concern for some traders.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Record Q3 results and stronger-than-expected Q4 guidance, attributed in part to gains from AppLovins AI advertising model and reinforced by expanded buybacks, fueled a sharp rally. Bulls welcomed a potential rebound, while skeptics questioned whether the growth can continue and warned the post-earnings surge could fade.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.

Why Did RVPH Stock Crash 40% In Pre-Market Today?

Equity

The company priced its $10 million offering at a 20% discount from Wednesday’s close.

Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 25,745 call options on the...

Why Did RVPH Stock Crash 50% Today?

The company announced that the FDA called for an additional Phase 3 trial of its schizophrenia treatment drug.

Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday...

Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 27,891 call options on the...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com...

Brokers Offer Predictions for RVPH FY2025 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings per share estimates for Reviva Pharmaceuticals in a research note issued...

Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.


Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

Reviva Pharmaceuticals Holdings Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>Reviva to use the proceeds for its Phase 3 RECOVER-2 trial for brilaroxazine to treat schizophrenia.</li><li>The company had earlier said that it plans to launch the RECOVER-2 Phase 3 trial in the first half of 2026.</li><li>Reviva implemented a 1-for-20 reverse share split on March 9.</li></ul>Shares of Reviva Pharmaceuticals Holdings (RVPH) plummeted more than 40% in pre-market trading on Thursday, after the company priced its public offering to raise about $10 million.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/RVPH">RVPH shares</a> would fall to a record low.<h2 class="st-heading-2">Offering At 20% Discount</h2>The offering consists of 6.67 million shares, as well as Series G and Series H warrants to purchase an equal number of shares, all priced at a combined $1.50 per share, for total gross proceeds of about $10 million. This represents a 20% discount on the stock’s closing price of $1.87 on Wednesday.Both warrants are immediately exercisable: Series G is valid for 5 years, and Series H expires in 12 months, the pharmaceutical company said. The offering is expected to close around March 20, 2026.Reviva said it plans to use the proceeds, along with existing cash, to support research and development, including its Phase 3 RECOVER-2 trial for brilaroxazine to treat schizophrenia. Funds will also be used for working capital and general corporate needs.<h2 class="st-heading-2">Reviva To Begin A Second Phase 3 Trial In First Half Of 2026</h2>In January, the U.S. Food and Drug Administration (FDA) recommended conducting a second Phase 3 trial for its schizophrenia drug candidate to get additional efficacy and safety data before submitting a New Drug Application (NDA).The company had earlier said that it plans to launch the RECOVER-2 Phase 3 trial in the first half of 2026, subject to funding. Reviva said existing data showed strong efficacy across key symptoms of schizophrenia and a favorable safety profile, with over 900 patients treated so far.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market slump, retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier.Chatter was mixed. One user said the stock’s upside looks “amazing” and the company may require $60 to $70 million to complete the study.<stembedurl>https://stocktwits.com/Blaze321/message/647942525</stembedurl>Another user said there was “no chance” of raising the required funds.<stembedurl>https://stocktwits.com/Gropius/message/647911923</stembedurl>Reviva had announced a 1-for-20 reverse share split earlier this month, with the stock trading on an ex-split basis from March 9.For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Reviva Pharmaceuticals Holdings company priced its $10 million offering at a 20% discount from Wednesday’s close.

More bullish

No change

More bearish

Too early to tell

Following the midterm results, how are you feeling about the market?

Stocktwits

Stocktwits Polls

$RVPH Track record of management is about as bad as it gets. Wonder what will happen to the nearly $20 million in cash? Somebody has got to be looking at that with a $5 million market cap.

Charlie Langworthy

$RVPH  
Guys, we really, really need another drastic and reverse split, to be Nasdaq compliant. I sent an email to Bhat to remind him to r/s as soon as possible! You are welcome guys!

Rupert McGillicuddy

$RVPH  thank you Distribution for posting the timeline.   
 
I can tell y'all this:  Not a single one of these timelines will be made.  Not one.  CEO has not ever met a single timeline since I held a large postion 4 years ago (got out long ago).  This is not a forecast, it is an automatic fact.  It became a sad joke among posters 4 years ago.   
 
In late October 2023 (3 EFFIN YEARS AGO!!) RVPH announced very good ph3 results to treat schizophrenia.  ZERO PROGRESS SINCE.  ZERO.  Only huge share price declines since.

Feed

News

Sentiment

Earnings

Fundamentals

Info

RVPH Reviva Pharmaceuticals Holdings Inc.

Fundamentals

Latest RVPH News